THERAPY DOSSIER · th-ad61c07092df

OA-GL12, a 12-residue peptide from the skin of the odorous frog Odorrana andersonii

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30842341 ↗2019Reported benefit

A short peptide potentially promotes the healing of skin wound.

MouseWoundmalen = Nine mice for the wound healing assay and a further nine fo…topical application to the wound0.1, 1 and 10 nM, 20 uL per woundfrom wounding to postoperative day 10

Model: Two full-thickness dorsal skin wounds, 8 x 8 mm

OA-GL12 accelerated wound closure in a time and concentration dependent manner, with healing rate at 10 nM reaching 95.03 +/- 1.90 percent by day 10, and showed no acute toxicity or haemolytic activity.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…